Syn-Tech Chen.&pharm (1777) reported revenue of NT$101 million for Oct 2026, -24.5% year on year and -24.0% from the previous month. Revenue for Jan–Oct 2026 was NT$1.08 billion (-2.6% year on year).
In Oct 2026, it ranked No. 72 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$101 million | -24.5% | -24.0% |
| Sep 2026 | NT$132.8 million | +22.1% | -1.5% |
| Aug 2026 | NT$134.8 million | +17.7% | +32.1% |
| Jul 2026 | NT$102.1 million | -10.0% | -18.9% |
| Jun 2026 | NT$125.9 million | +28.2% | +15.2% |
| May 2026 | NT$109.2 million | -6.7% | +7.9% |
| Apr 2026 | NT$101.3 million | -7.5% | +16.0% |
| Mar 2026 | NT$87.3 million | +3.9% | -14.0% |
| Feb 2026 | NT$101.6 million | -24.9% | +17.1% |
| Jan 2026 | NT$86.7 million | -10.1% | +4.7% |
| Dec 2025 | NT$82.8 million | -12.4% | -22.2% |
| Nov 2025 | NT$106.4 million | -2.0% | -20.5% |
| Oct 2025 | NT$133.8 million | +20.2% | +23.0% |
| Sep 2025 | NT$108.8 million | +2.2% | -5.1% |
| Aug 2025 | NT$114.6 million | -6.6% | +1.1% |
| Jul 2025 | NT$113.4 million | +11.7% | +15.5% |
| Jun 2025 | NT$98.2 million | -24.3% | -16.2% |
| May 2025 | NT$117.1 million | +1.8% | +6.9% |
| Apr 2025 | NT$109.5 million | +11.4% | +30.3% |
| Mar 2025 | NT$84 million | -3.3% | -37.9% |
| Feb 2025 | NT$135.2 million | +33.6% | +40.2% |
| Jan 2025 | NT$96.5 million | +18.1% | +2.1% |
| Dec 2024 | NT$94.5 million | +6.7% | -13.0% |
| Nov 2024 | NT$108.5 million | +0.5% | -2.5% |
| Oct 2024 | NT$111.3 million | +47.7% | +4.6% |
Jan–Oct 2026 cumulative: NT$1.08 billion (-2.6% YoY)
Other Biotech & Medical companies
Compare with peers: Syn-Tech Chen.&pharm vs PEC / Syn-Tech Chen.&pharm vs Lotus Pharm / Syn-Tech Chen.&pharm vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16